Carbonic Anhydrase IX Enzyme in Triple Negative Breast Carcinoma

NCT06309459 | Completed

• 1 other identifier: IRB 2023/04-34
• Study Type: observational
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

Triple-negative breast carcinoma is characterized by the absence of estrogen receptors, progesterone receptors, and HER2/neu receptors. Carbonic anhydrase IX (CA IX) is a tumor-associated cell surface glycoprotein that is involved in adaptation to hypoxia-induced acidosis and plays a role in cancer progression. This study aimed to investigate CA IX expression in TNBC and its relationship with treatment effect.

Conditions

Triple Negative Breast Cancer; Carbonic Anhydrase IX

Keywords

Triple negative breast carcinoma; Carbonic anhydrase IX; Treatment effect; Ki67 proliferation index

Outcome Measures

Primary Outcomes (2)

• Poor prognostic factors in patients with TNBC

  Higher staining CA IX levels (≥ 10%) in TNBC patients' pathological specimens is a poor prognostic factor

  2018-2023

• The treatment success with inhibiting the CA IX enzyme levels' effectiveness

  Treatment success in TNBC patients by evaluating changes in CA IX staining levels

  2018-2023

Study Arms (2)

Low Staining

CA IX is a transmembrane protein, it exhibits cytoplasmic membrane staining. Immunohistochemically positive cells were graded as Low staining if they constituted \<10% of the total.

Diagnostic Test: Carbonic anhydrase staining levels

High Staining

CA IX is a transmembrane protein, it exhibits cytoplasmic membrane staining. Immunohistochemically positive cells were graded as high staining if they constituted ≥ 10%

Diagnostic Test: Carbonic anhydrase staining levels

Interventions

Carbonic anhydrase staining levels DIAGNOSTIC_TEST

CA IX is a transmembrane protein, it exhibits cytoplasmic membrane staining. Immunohistochemically positive cells were graded as Low staining if they constituted \<10% of the total and high staining if they constituted ≥ 10% (15).

High Staining; Low Staining

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Triple Negative Breast Cancer cases who were operated in Elazığ Fethi Sekin SUAM

You may qualify if:

• Older than 18 years
• Triple-negative mastectomy cases
• Patients whose data can be available
• Patients who were operated in our hospital

You may not qualify if:

• Younger than 18 years
• Not triple negative mastectomy cases
• Patients with missing data
• Patients who were operated in another hospital

Sponsors & Collaborators

• Kahramanmaras Sutcu Imam University: lead

Study Sites (1)

Kahramanmaraş Sütçü İmam University

Kahramanmaraş, 46000, Turkey (Türkiye)

Location

Related Publications (9)

• Bakherad H, Ghasemi F, Hosseindokht M, Zare H. Nanobodies; new molecular instruments with special specifications for targeting, diagnosis and treatment of triple-negative breast cancer. Cancer Cell Int. 2022 Aug 6;22(1):245. doi: 10.1186/s12935-022-02665-0.

  PMID: 35933373 BACKGROUND

• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.

  PMID: 33538338 BACKGROUND

• Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020 Jun 9;22(1):61. doi: 10.1186/s13058-020-01296-5.

  PMID: 32517735 BACKGROUND

• Warburg O, Wind F, Negelein E. THE METABOLISM OF TUMORS IN THE BODY. J Gen Physiol. 1927 Mar 7;8(6):519-30. doi: 10.1085/jgp.8.6.519. No abstract available.

  PMID: 19872213 BACKGROUND

• Carroll CP, Bolland H, Vancauwenberghe E, Collier P, Ritchie AA, Clarke PA, Grabowska AM, Harris AL, McIntyre A. Targeting hypoxia regulated sodium driven bicarbonate transporters reduces triple negative breast cancer metastasis. Neoplasia. 2022 Mar;25:41-52. doi: 10.1016/j.neo.2022.01.003. Epub 2022 Feb 9.

  PMID: 35150959 BACKGROUND

• Lee P, Chandel NS, Simon MC. Cellular adaptation to hypoxia through hypoxia inducible factors and beyond. Nat Rev Mol Cell Biol. 2020 May;21(5):268-283. doi: 10.1038/s41580-020-0227-y. Epub 2020 Mar 6.

  PMID: 32144406 BACKGROUND

• Godet I, Doctorman S, Wu F, Gilkes DM. Detection of Hypoxia in Cancer Models: Significance, Challenges, and Advances. Cells. 2022 Feb 16;11(4):686. doi: 10.3390/cells11040686.

  PMID: 35203334 BACKGROUND

• Gillies RJ, Brown JS, Anderson ARA, Gatenby RA. Eco-evolutionary causes and consequences of temporal changes in intratumoural blood flow. Nat Rev Cancer. 2018 Sep;18(9):576-585. doi: 10.1038/s41568-018-0030-7.

  PMID: 29891961 BACKGROUND

• Wu Q, You L, Nepovimova E, Heger Z, Wu W, Kuca K, Adam V. Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape. J Hematol Oncol. 2022 Jun 3;15(1):77. doi: 10.1186/s13045-022-01292-6.

  PMID: 35659268 BACKGROUND

Biospecimen

Retention: SAMPLES WITHOUT DNA

Postop mastectomy pathologic materials

MeSH Terms

Conditions

Triple Negative Breast Neoplasms

Condition Hierarchy (Ancestors)

Breast Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor, Associate

Study Record Dates

• First Submitted: January 10, 2024
• First Posted: March 13, 2024
• Study Start: August 1, 2018
• Primary Completion: May 1, 2023
• Study Completion: May 1, 2023
• Last Updated: March 13, 2024

Record last verified: 2024-03

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)